Balyasny Asset Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-114,512
Closed -$1.59M 3014
2024
Q2
$1.59M Buy
+114,512
New +$1.62M ﹤0.01% 1612
2024
Q1
Sell
-30,157
Closed -$488K 2943
2023
Q4
$488K Buy
+30,157
New +$493K ﹤0.01% 1959
2023
Q3
Sell
-326,485
Closed -$5.25M 2565
2023
Q2
$5.25M Buy
326,485
+257,992
+377% +$4.25M 0.01% 1033
2023
Q1
$1.19M Buy
68,493
+65,957
+2,601% +$940K ﹤0.01% 1677
2022
Q4
$23.4K Sell
2,536
-22,773
-90% -$212K ﹤0.01% 2463
2022
Q3
$218K Sell
25,309
-1,504,832
-98% -$14.9M ﹤0.01% 2291
2022
Q2
$12.5M Buy
1,530,141
+1,270,632
+490% +$12.1M 0.04% 579
2022
Q1
$3.15M Sell
259,509
-136,372
-34% -$2.87M 0.01% 1156
2021
Q4
$13.5M Buy
+395,881
New +$15.5M 0.05% 547
2021
Q2
Sell
-146,931
Closed -$7.09M 2217
2021
Q1
$7.09M Buy
+146,931
New +$7.65M 0.03% 579
2020
Q1
Sell
-42,922
Closed -$1.25M 1402
2019
Q4
$1.25M Buy
+42,922
New +$1.02M 0.01% 845
2019
Q3
Sell
-94,386
Closed -$2.07M 1442
2019
Q2
$2.07M Buy
94,386
+67,468
+251% +$1.48M 0.01% 872
2019
Q1
$551K Buy
+26,918
New +$468K ﹤0.01% 1182
2016
Q3
Sell
-16,772
Closed -$135K 1185
2016
Q2
$135K Buy
+16,772
New +$134K ﹤0.01% 1077
2015
Q3
Sell
-22,390
Closed -$121K 1305
2015
Q2
$121K Buy
22,390
+1,390
+7% +$7.17K ﹤0.01% 1063
2015
Q1
$98K Buy
+21,000
New +$91.3K ﹤0.01% 893

Other funds holding NEO

Balyasny Asset Management's NEO Position: Q3 2024 in Review

Balyasny Asset Management sold out of NeoGenomics (NEO) in Q3 2024, closing a stake of 114,512 shares — an estimated $1.59M sold.

Balyasny Asset Management first reported a position in NEO in Q1 2015 and held it in 16 quarters. The position peaked at $13.5M in Q4 2021. 270 funds tracked by Wall St. Rank hold NEO as of Q3 2024.

  • Balyasny Asset Management reported no remaining NeoGenomics position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 114,512 NeoGenomics shares in Q3 2024, an estimated $1.59M.
  • Balyasny Asset Management first reported a position in NeoGenomics in Q1 2015 and held it in 16 quarters.
  • Balyasny Asset Management's NeoGenomics position peaked at $13.5M in Q4 2021.
  • 270 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.